CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
85 hedge funds and large institutions have $101M invested in CTI BioPharma Corp. (DE) Common Stock in 2014 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 23 reducing their positions, and 16 closing their positions.
1,146% more call options, than puts
Call options by funds: $2.31M | Put options by funds: $185K
9% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 23
4% less funds holding
Funds holding: 89 → 85 (-4)
13% less capital invested
Capital invested by funds: $116M → $101M (-$15.2M)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$2.26M |
| 2 |
Jane Street
New York
|
+$1.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$839K |
| 4 |
Renaissance Technologies
New York
|
+$827K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$761K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$2.42M |
| 2 |
Millennium Management
New York
|
-$895K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$871K |
| 4 |
CCMH
Cornerstone Capital Management Holdings
New York
|
-$822K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$730K |
CTIC Hedge Fund Activity: Q3 2014 in Review
85 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2014, worth a combined $101M — down 13% from $116M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CTIC and 12 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 25 added.
The largest buyer was Eagle Asset Management, adding an estimated $2.26M. The largest seller was State Street, cutting an estimated $2.42M.
- 85 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2014, down from 89 in Q2 2014.
- Funds reported $101M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2014, down 13% quarter-over-quarter.
- 12 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2014 and 16 closed out, a net change of -4 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2014 was Eagle Asset Management, an estimated $2.26M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2014 was State Street, an estimated $2.42M sold.
Based on aggregated 13F filings for Q3 2014.